# 2026-23513: DEA Revokes Doctor’s Controlled-Substance Registration After Virginia Authorization Ends

2026-23513, Kyndahl D. Bertram, D.O.; Decision and Order, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-11-18, effective 2026-12-18; PRIA reads it as touching household money (as of 2026-11-18).

- Canonical: https://policyrisk.com/federal-register/2026-23513
- As of: 2026-11-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23513
- Title: Kyndahl D. Bertram, D.O.; Decision and Order
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 74195
- Published: 2026-11-18
- Effective: 2026-12-18
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-18

## In one line

DEA Revokes Doctor’s Controlled-Substance Registration After Virginia Authorization Ends

## Summary

Dr. Kyndahl D. Bertram lost her DEA registration because she no longer has permission to handle controlled substances in Virginia. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on July 31, 2026. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.

## Effects PRIA read

- DEA Registration Revoked: cost, high. The Drug Enforcement Administration revoked DEA Certificate of Registration No. FB9918357 for Kyndahl D. Bertram, D.O. The revocation is effective December 18, 2026, and means she is not authorized to prescribe, administer, dispense, or otherwise handle controlled substances in Virginia.
- Pending Renewal and New Registrations Denied: cost, medium. The DEA denied any pending applications by Kyndahl D. Bertram, D.O., to renew or modify her registration and denied any pending applications for additional registration in Virginia. That denial is ordered alongside the revocation and is effective December 18, 2026.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-23075](https://policyrisk.com/federal-register/2026-23075): Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV, 2026-11-12
- [2026-23006](https://policyrisk.com/federal-register/2026-23006): Importer of Controlled Substances Application: NSI Lab Solutions LLC, 2026-11-12

## Sources
- [2026-23513 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/18/2026-23513/kyndahl-d-bertram-do-decision-and-order)
- [2026-23513 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-18/pdf/2026-23513.pdf)

## Related
- [Previous: 2026-23511, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Co…](https://policyrisk.com/federal-register/2026-23511)
- [Next: 2026-23515, Notice of Revised National Environmental Policy Act Implementing Procedures](https://policyrisk.com/federal-register/2026-23515)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23513 (as of 2026-11-18).
